NRX Pharmaceuticals, Inc.
NRXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001719406
No open-market purchases or sales by NRX Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $47.6M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding NRX Pharmaceuticals, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 34 | 37 | +3 |
| Shares | 10.3M | 3.64M | −6.62M (−64.5%) |
| Value | $25.1M | $2.18M | −$23.0M (−91.3%) |
New holders (8)
Institutions that held NRX Pharmaceuticals, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 296,815 | $178.0K | 0.00% |
| Bridgeway Capital Management, LLC | 153,700 | $92.0K | 0.00% |
| Citadel Advisors LLC | 91,666 | $55.0K | 0.00% |
| Two Sigma Investments, LP | 41,451 | $25.0K | 0.00% |
| HighPoint Advisor Group LLC | 43,501 | $24.0K | 0.00% |
| Virtu Financial LLC | 12,799 | $8.00K | 0.00% |
| Wealthcare Advisory Partners LLC | 13,000 | $8.00K | 0.00% |
| Royal Bank of Canada | 523 | $0 | 0.00% |
Sold out (5)
Institutions that held NRX Pharmaceuticals, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Armistice Capital, LLC | 6,259,781 | $15.3M |
| CVI Holdings, LLC | 625,978 | $1.53M |
| Cubist Systematic Strategies, LLC | 20,541 | $50.0K |
| Ursa Fund Management, LLC | 15,000 | $37.0K |
| Charles Schwab Investment Management Inc | 12,000 | $30.0K |